Success Stories: An Indian Manager of Quality Control in Pharmaceutical Drug Development Wins EB1-A Approval in Just 13 Days Due to Premium Processing Upgrade and Our Team’s Work

Client’s Testimonial:

“My experience in working with you and your team has been great.”

On January 4^th, 2023, we received another EB-1A (Alien of Extraordinary Ability) approval for a Manager of Quality Control in the Field of Pharmaceutical Drug Development (Approval Notice).

General Field: Pharmaceutical Drug Development

Position at the Time of Case Filing: Manager of Quality Control

Country of Origin: India

State of Residence at the Time of Filing: North Carolina

Approval Notice Date: January 4^th, 2023

Processing Time: 13 days (Premium Processing Requested)

Case Summary:

North America Immigration Law Group specializes in representing clients from all over the country for I-140 immigration petitions. We specialize in employment-based immigration petitions and have a proven record of success. With over 32,000 successes we have first-hand knowledge of how USCIS adjudicates on I-140 cases.

So when we get clients who want to apply under any of the varied categories of EB1-A, NIW, EB-1-B, O1-A, etc. our team first makes sure to explain the process of adjudication to them and then do an initial background check of their academic and professional career thus far. So when a leading expert in the development of analytical bioassays for pharmaceuticals and biopharmaceuticals, including cell and gene therapy (CGT) products, in the field of pharmaceutical drug development, approached our firm, we took the initial steps and then having signed the retainer, began working on his petition. Our team was able to gather the following from the documents he furnished:

He has achieved a consistent and notable record of success and influence in these areas of study and the field has recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 21 times.
His work has resulted in 5 peer-reviewed scientific articles and 1 book chapter and these publications have been cited 212 times by researchers in at least 27 countries according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pharmaceutical drug development.
Due to its clear implications for the development of cell-based bioassays and their applications in creating novel biopharmaceuticals, his research has already attracted the attention of the private sector.
Not only has he shown that he meets at least three of the regulatory criteria, but the evidence in the aggregate also demonstrates his national and international acclaim and position at the very top of his field.
Finally, we also collected 4 letters of recommendation from other experts which helped corroborate the information we had already provided.

Thus our team showed that his work on novel therapeutic product research has been essential and transformative in the field of pharmaceutical drug development and is thus of use to the United States. We were also able to prove that his work was indeed extraordinary too and thus should continue in the county. So when the approval came through after only 13 days, we were proud and happy to have worked on the case and we wish our client a very successful future.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.